Significance of hepatitis virus infection in the oncogenic initiation of hepatocellular carcinoma

World Journal of Gastroenterology

Volumn 22, Issue 4, 2016, Pages 1497-1512

  Sukowati, Caecilia H C ^a,b   El Khobar, Korri E ^c,d   Ie, Susan I ^c   Anfuso, Beatrice ^a   Muljono, David H ^c   Tiribelli, Claudio ^a,b  

^a CBM Scrl Area Science Park Basovizza   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c EIJKMAN INSTITUTE FOR MOLECULAR BIOLOGY   (Indonesia)

^d UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Oncogenicity; Viral pathogenicity

Indexed keywords

VIRAL PROTEIN;

CARCINOGENICITY; COINFECTION; ENDOPLASMIC RETICULUM STRESS; GENE MUTATION; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS DELTA VIRUS; HUMAN; LIVER CELL; LIVER CELL CARCINOMA; NONHUMAN; OXIDATIVE STRESS; REVIEW; RISK FACTOR; STEM CELL; VIRUS VIRULENCE; ANIMAL; CANCER STEM CELL; CARCINOMA, HEPATOCELLULAR; CHRONIC HEPATITIS B; CHRONIC HEPATITIS C; COMPLICATION; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; HEPACIVIRUS; HOST PATHOGEN INTERACTION; LIVER NEOPLASMS; METABOLISM; ONCOGENE; PATHOGENICITY; PATHOLOGY; VIROLOGY; VIRUS CELL TRANSFORMATION;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION, VIRAL; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE EXPRESSION REGULATION, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HOST-PATHOGEN INTERACTIONS; HUMANS; LIVER NEOPLASMS; NEOPLASTIC STEM CELLS; ONCOGENES; RISK FACTORS;

EID: 84964683305     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/WJG.V22.I4.1497     Document Type: Review

References (210)

1. El-Serag HB. Hepatocellular carcinoma. N Engl J Med 2011; 365: 1118-1127 [PMID: 21992124 DOI: 10.1056/NEJMra1001683]
2. Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer 2013; 132: 1133-1145 [PMID: 22752881 DOI: 10.1002/ijc.27711]
3. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI: 10.1002/ijc.29210]
4. Stewart BW, Wild CP, editors. World Cancer Report 2014. Lyon, France: International Agency for Research on Cancer, 2014
5. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980-2004. Hepatology 2008; 48: 137-145 [PMID: 18537177 DOI: 10.1002/hep.22312]
6. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255 [PMID: 22353262 DOI: 10.1016/S0140-6736(11)61347-0]
7. Caldwell S, Park SH. The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol 2009; 44 Suppl 19: 96-101 [PMID: 19148801 DOI: 10.1007/s00535-008-2258-6]
8. Alkofer B, Lepennec V, Chiche L. Hepatocellular cancer in the non-cirrhotic liver. J Visc Surg 2011; 148: 3-11 [PMID: 21306970 DOI: 10.1016/j.jviscsurg.2010.12.012]
9. Bosetti C, Turati F, La Vecchia C. Hepatocellular carcinoma epidemiology. Best Pract Res Clin Gastroenterol 2014; 28: 753-770 [PMID: 25260306 DOI: 10.1016/j.bpg.2014.08.007]
10. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012; 142: 1264-1273.e1 [PMID: 22537432 DOI: 10.1053/j.gastro.2011.12.061]
11. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943 [PMID: 22424438 DOI: 10.1016/j.jhep.2011.12.001]
12. Fong ZV, Tanabe KK. The clinical management of hepatocellular carcinoma in the United States, Europe, and Asia: a comprehensive and evidence-based comparison and review. Cancer 2014; 120: 2824-2838 [PMID: 24897995 DOI: 10.1002/cncr.28730]
13. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-2576 [PMID: 17570226 DOI: 10.1053/j.gastro.2007.04.061]
14. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008; 48: 1312-1327 [PMID: 18821591 DOI: 10.1002/hep.22506]
15. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol 2010; 80: 550-560 [PMID: 20371362 DOI: 10.1016/j.bcp.2010.03.034]
16. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-390 [PMID: 18650514 DOI: 10.1056/NEJMoa0708857]
17. Lachenmayer A, Alsinet C, Savic R, Cabellos L, Toffanin S, Hoshida Y, Villanueva A, Minguez B, Newell P, Tsai HW, Barretina J, Thung S, Ward SC, Bruix J, Mazzaferro V, Schwartz M, Friedman SL, Llovet JM. Wnt-pathway activation in two molecular classes of hepatocellular carcinoma and experimental modulation by sorafenib. Clin Cancer Res 2012; 18: 4997-5007 [PMID: 22811581 DOI: 10.1158/1078-0432.CCR-11-2322]
18. Shlomai A, de Jong YP, Rice CM. Virus associated malignancies: the role of viral hepatitis in hepatocellular carcinoma. Semin Cancer Biol 2014; 26: 78-88 [PMID: 24457013 DOI: 10.1016/j.semcancer.2014.01.004]
19. Dandri M, Locarnini S. New insight in the pathobiology of hepatitis B virus infection. Gut 2012; 61 Suppl 1: i6-17 [PMID: 22504921 DOI: 10.1136/gutjnl-2012-302056]
20. World Health Organization. Hepatitis B Fact Sheet no.204, updated July 2015. Available from: URL: http://www.who.int/mediacentre/factsheets/fs204/en/
21. Sherman M. Hepatocellular carcinoma: New and emerging risks. Dig Liver Dis 2010; 42 Suppl 3: S215-S222 [PMID: 20547306 DOI: 10.1016/S1590-8658(10)60508-7]
22. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham A, Adair T, Aggarwal R, Ahn SY, AlMazroa MA, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, Bell ML, Benjamin EJ, Bennett D, Bhalla K, Bikbov B, bin Abdulhak A, Birbeck G, Blyth F, Bolliger I, Boufous SA, Bucello C, Burch M, Burney P, Carapetis J, Chen HL, Chou D, Chugh SS, Coffeng LE, Colan SD, Colquhoun S, Colson KE, Condon J, Connor MD, Cooper LT, Corriere M, Cortinovis M, Courville de Vaccaro K, Couser W, Cowie BC, Criqui MH, Cross M, Dabhadkar KC, Dahodwala N, De Leo D, Degenhardt L, Delossantos A, Denenberg J, Des Jarlais DC, Dharmaratne SD, Dorsey ER, Driscoll T, Duber H, Ebel B, Erwin PJ, Espindola P, Ezzati M, Feigin V, Flaxman AD, Forouzanfar MH, Fowkes FGR, Franklin R, Fransen M, Freeman MK, Gabriel SE, Gakidou E, Gaspari F, Gillum RF, Gonzalez-Medina D, Halasa YA, Haring D, Harrison JE, Havmoeller R, Hay RJ, Hoen B, Hotez PJ, Hoy D, Jacobsen KH, James SL, Jasrasaria R, Jayaraman S, Johns N, Karthikeyan G, Kassebaum N, Keren A, Khoo JP, Knowlton LM, Kobusingye O, Koranteng A, Krishnamurthi R, Lipnick M, Lipshultz SE, Lockett Ohno S, Mabweijano J, MacIntyre MF, Mallinger L, March L, Marks GB, Marks R, Matsumori A, Matzopoulos R, Mayosi BM, McAnulty JH, McDermott MM, McGrath J, Memish ZA, Mensah GA, Merriman TR, Michaud C, Miller M, Miller TR, Mock C, Mocumbi AO, Mokdad AA, Moran A, Mulholland k, Nair MN, Naldi L, Narayan KMV, Nasseri K, Norman P, O’Donnell M, Omer SB, Ortblad K, Osborne R, Ozgediz D, Pahari B, Pandian JD, Panozo Rivero A, Perez Padilla R, Perez-Ruiz F, Perico N, Phillips D, Pierce K, Pope III CA, Porrini E, Pourmalek F, Raju M, Ranganathan D, Rehm JT, Rein DB, Remuzzi G, Rivara FP, Roberts T, Rodriguez De León F, Rosenfeld LC, Rushton L, Sacco RL, Salomon JA, Sampson U, Sanman E, Schwebel DC, Segui-Gomez M, Shepard DS, Singh D, Singleton J, Sliwa K, Smith E, Steer A, Taylor JA, Thomas B, Tleyjeh IM, Towbin JA, Truelsen T, Undurraga EA, Venketasubramanian N, Vijayakumar L, Vos T, Wagner GR, Wang MR, Wang WZ, Watt K, Weinstock MA, Weintraub R, Wilkinson JD, Woolf AD, Wulf S, Yeh PH, Yip P, Zabetian A, Zheng ZJ, Lopez AD, Murray CJL. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2095-2128 [PMID: 23245604 DOI: 10.1016/S0140-6736(12)61728-0]
23. Bosch FX, Ribes J, Díaz M, Cléries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16 [PMID: 15508102]
24. Chen CJ, Yang HI, Su J, Jen CL, You SL, Lu SN, Huang GT, Iloeje UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73 [PMID: 16391218 DOI: 10.1001/jama.295.1.65]
25. Kim GA, Lee HC, Kim MJ, Ha Y, Park EJ, An J, Lee D, Shim JH, Kim KM, Lim YS. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance. J Hepatol 2015; 62: 1092-1099 [PMID: 25445399 DOI: 10.1016/j.jhep.2014.11.031]
26. Li Y, Zhang Z, Shi J, Jin L, Wang L, Xu D, Wang FS. Risk factors for naturally-occurring early-onset hepatocellular carcinoma in patients with HBV-associated liver cirrhosis in China. Int J Clin Exp Med 2015; 8: 1205-1212 [PMID: 25785114]
27. Pollack HJ, Kwon SC, Wang SH, Wyatt LC, Trinh-Shevrin C. Chronic hepatitis B and liver cancer risks among Asian immigrants in New York City: Results from a large, community-based screening, evaluation, and treatment program. Cancer Epidemiol Biomarkers Prev 2014; 23: 2229-2239 [PMID: 25368398 DOI: 10.1158/1055-9965.EPI-14-0491]
28. Shimakawa Y, Lemoine M, Bottomley C, Njai HF, Ndow G, Jatta A, Tamba S, Bojang L, Taal M, Nyan O, D’Alessandro U, Njie R, Thursz M, Hall AJ. Birth order and risk of hepatocellular carcinoma in chronic carriers of hepatitis B virus: a case-control study in The Gambia. Liver Int 2015; 35: 2318-2326 [PMID: 25728498 DOI: 10.1111/liv.12814]
29. van Bömmel F, Berg T. Treatment of HBV related cirrhosis. Liver Int 2013; 33 Suppl 1: 176-181 [PMID: 23286862 DOI: 10.1111/liv.12074]
30. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845 DOI: S0168-8278(12)00167-5]
31. Liaw YF, Kao JH, Piratvisuth T, Chan HL, Chien RN, Liu CJ, Gane E, Locarnini S, Lim SG, Han KH, Amarapurkar D, Cooksley G, Jafri W, Mohamed R, Hou JL, Chuang WL, Lesmana LA, Sollano JD, Suh DJ, Omata M. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-561 [PMID: 26201469 DOI: 10.1007/s12072-012-9365-4]
32. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190]
33. World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland: WHO Press, 2015
34. Ang LW, Tey SH, Cutter J, James L, Goh KT. Seroprevalence of hepatitis B virus infection among children and adolescents in Singapore, 2008-2010. J Med Virol 2013; 85: 583-588 [PMID: 23400872 DOI: 10.1002/jmv.23496]
35. Chiang CJ, Yang YW, You SL, Lai MS, Chen CJ. Thirty-year outcomes of the national hepatitis B immunization program in Taiwan. JAMA 2013; 310: 974-976 [PMID: 24002285 DOI: 10.1001/jama.2013.276701]
36. Hsu HM, Lee SC, Wang MC, Lin SF, Chen DS. Efficacy of a mass hepatitis B immunization program after switching to recombinant hepatitis B vaccine: a population-based study in Taiwan. Vaccine 2001; 19: 2825-2829 [PMID: 11282193 DOI: 10.1016/S0264-410X(01)00015-9]
37. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, Chu HC, Wu TC, Yang SS, Kuo HS, Chen DS. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355 [PMID: 19759364 DOI: 10.1093/jnci/djp288]
38. Chang MH, Chen DS. Prevention of hepatitis B. Cold Spring Harb Perspect Med 2015; 5: a021493 [PMID: 25732034 DOI: 10.1101/cshperspect.a021493]
39. Chan HL, Wong ML, Hui AY, Hung LC, Chan FK, Sung JJ. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol 2003; 41: 1277-1279 [PMID: 12624067]
40. Kramvis A. Genotypes and genetic variability of hepatitis B virus. Intervirology 2014; 57: 141-150 [PMID: 25034481 DOI: 10.1159/000360947]
41. Pourkarim MR, Amini-Bavil-Olyaee S, Kurbanov F, Van Ranst M, Tacke F. Molecular identification of hepatitis B virus genotypes/subgenotypes: revised classification hurdles and updated resolutions. World J Gastroenterol 2014; 20: 7152-7168 [PMID: 24966586 DOI: 10.3748/wjg.v20.i23.7152]
42. Kramvis A, Kew M, François G. Hepatitis B virus genotypes. Vaccine 2005; 23: 2409-2423 [PMID: 15752827 DOI: S0264-410X(04)00849-7]
43. Kurbanov F, Tanaka Y, Mizokami M. Geographical and genetic diversity of the human hepatitis B virus. Hepatol Res 2010; 40: 14-30 [PMID: 20156297 DOI: HEP601]
44. Thedja MD, Muljono DH, Nurainy N, Sukowati CH, Verhoef J, Marzuki S. Ethnogeographical structure of hepatitis B virus genotype distribution in Indonesia and discovery of a new subgenotype, B9. Arch Virol 2011; 156: 855-868 [PMID: 21318309 DOI: 10.1007/s00705-011-0926-y]
45. Westland C, Delaney W, Yang H, Chen SS, Marcellin P, Hadziyannis S, Gish R, Fry J, Brosgart C, Gibbs C, Miller M, Xiong S. Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil1. Gastroenterology 2003; 125: 107-116 [PMID: 12851876 DOI: S0016508503007005]
46. Liu S, Zhang H, Gu C, Yin J, He Y, Xie J, Cao G. Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis. J Natl Cancer Inst 2009; 101: 1066-1082 [PMID: 19574418 DOI: 10.1093/jnci/djp180]
47. Orito E, Mizokami M. Differences of HBV genotypes and hepatocellular carcinoma in Asian countries. Hepatol Res 2007; 37: S33-S35 [PMID: 17627633 DOI: 10.1111/j.1872-034X.2007.00101.x]
48. Kao JH. Hepatitis B virus genotypes and hepatocellular carcinoma in Taiwan. Intervirology 2003; 46: 400-407 [PMID: 14688459]
49. Orito E, Mizokami M. Hepatitis B virus genotypes and hepatocellular carcinoma in Japan. Intervirology 2003; 46: 408-412 [PMID: 14688460]
50. Sumi H, Yokosuka O, Seki N, Arai M, Imazeki F, Kurihara T, Kanda T, Fukai K, Kato M, Saisho H. Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease. Hepatology 2003; 37: 19-26 [PMID: 12500184 DOI: 10.1053/jhep.2003.50036]
51. Zhao H, Kurbanov F, Wan MB, Yin YK, Niu JQ, Hou JL, Wei L, Wang GQ, Tanaka Y, Mizokami M, Si CW. Genotype B and younger patient age associated with better response to low-dose therapy: a trial with pegylated/nonpegylated interferon-alpha-2b for hepatitis B e antigen-positive patients with chronic hepatitis B in China. Clin Infect Dis 2007; 44: 541-548 [PMID: 17243057 DOI: 10.1086/511042]
52. Wong GL, Chan HL, Yiu KK, Lai JW, Chan VK, Cheung KK, Wong EW, Wong VW. Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma. Aliment Pharmacol Ther 2013; 37: 517-526 [PMID: 23305043 DOI: 10.1111/apt.12207]
53. Datta S, Roychoudhury S, Ghosh A, Dasgupta D, Ghosh A, Chakraborty BC, Ray S, Gupta S, Santra AK, Datta S, Das K, Dhali GK, Chowdhury A, Banerjee S. Distinct distribution pattern of hepatitis B virus genotype C and D in liver tissue and serum of dual genotype infected liver cirrhosis and hepatocellular carcinoma patients. PLoS One 2014; 9: e102573 [PMID: 25032957 DOI: 10.1371/journal.pone.0102573]
54. Constantinescu I, Dinu AA, Boscaiu V, Niculescu M. Hepatitis B virus core promoter mutations in patients with chronic hepatitis B and hepatocellular carcinoma in bucharest, romania. Hepat Mon 2014; 14: e22072 [PMID: 25477976 DOI: 10.5812/hepatmon.22072]
55. Kao JH, Chen PJ, Lai MY, Chen DS. Basal core promoter mutations of hepatitis B virus increase the risk of hepatocellular carcinoma in hepatitis B carriers. Gastroenterology 2003; 124: 327-334 [PMID: 12557138 DOI: 10.1053/gast.2003.50053]
56. Khan M, Dong JJ, Acharya SK, Dhagwahdorj Y, Abbas Z, Jafri SMW, Mulyono DH, Tozun N, Sarin SK. Hepatology issues in Asia: Perspectives from regional leaders. J Gastroenterol Hepatol 2004; 19: S419-S430
57. Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol 2002; 37: 355-363 [PMID: 12175631]
58. Datta S, Ghosh A, Dasgupta D, Ghosh A, Roychoudhury S, Roy G, Das S, Das K, Gupta S, Basu K, Basu A, Datta S, Chowdhury A, Banerjee S. Novel point and combo-mutations in the genome of hepatitis B virus-genotype D: characterization and impact on liver disease progression to hepatocellular carcinoma. PLoS One 2014; 9: e110012 [PMID: 25333524 DOI: 10.1371/journal.pone.0110012]
59. Oba U, Koga Y, Hoshina T, Suminoe A, Abe K, Hayashida M, Taguchi T, Hara T. An adolescent female having hepatocellular carcinoma associated with hepatitis B virus genotype H with a deletion mutation in the pre-S2 region. J Infect Chemother 2015; 21: 302-304 [PMID: 25442807 DOI: 10.1016/j.jiac.2014.10.015]
60. Hadziyannis S, Gerber MA, Vissoulis C, Popper H. Cytoplasmic hepatitis B antigen in “ground-glass” hepatocytes of carriers. Arch Pathol 1973; 96: 327-330 [PMID: 4582440]
61. Hsieh YH, Chang YY, Su IJ, Yen CJ, Liu YR, Liu RJ, Hsieh WC, Tsai HW, Wang LH, Huang W. Hepatitis B virus pre-S2 mutant large surface protein inhibits DNA double-strand break repair and leads to genome instability in hepatocarcinogenesis. J Pathol 2015; 236: 337-347 [PMID: 25775999 DOI: 10.1002/path.4531]
62. Su IJ, Wang LH, Hsieh WC, Wu HC, Teng CF, Tsai HW, Huang W. The emerging role of hepatitis B virus pre-S2 deletion mutant proteins in HBV tumorigenesis. J Biomed Sci 2014; 21: 98 [PMID: 25316153 DOI: 10.1186/s12929-014-0098-7]
63. Wang HC, Huang W, Lai MD, Su IJ. Hepatitis B virus pre-S mutants, endoplasmic reticulum stress and hepatocarcinogenesis. Cancer Sci 2006; 97: 683-688 [PMID: 16863502 DOI: 10.1111/j.1349-7006.2006.00235.x]
64. Muroyama R, Kato N, Yoshida H, Otsuka M, Moriyama M, Wang Y, Shao RX, Dharel N, Tanaka Y, Ohta M, Tateishi R, Shiina S, Tatsukawa M, Fukai K, Imazeki F, Yokosuka O, Shiratori Y, Omata M. Nucleotide change of codon 38 in the X gene of hepatitis B virus genotype C is associated with an increased risk of hepatocellular carcinoma. J Hepatol 2006; 45: 805-812 [PMID: 17050029 DOI: 10.1016/j.jhep.2006.07.025]
65. Smedile A, Farci P, Verme G, Caredda F, Cargnel A, Caporaso N, Dentico P, Trepo C, Opolon P, Gimson A, Vergani D, Williams R, Rizzetto M. Influence of delta infection on severity of hepatitis B. Lancet 1982; 2: 945-947 [PMID: 6127458 DOI: S0140-6736(82)90156-8]
66. Keshvari M, Alavian SM, Aghaee B, Behnava B, Mahdavi M, Fesharaki MG, Sharafi H. Seroepidemiology and clinical features of hepatitis delta among HBsAg carriers: a study from Hepatitis Clinic of Iranian Blood Transfusion Organization. Transfus Med 2014; 24: 411-417 [PMID: 25523297 DOI: 10.1111/tme.12163]
67. Shirvani-Dastgerdi E, Amini-Bavil-Olyaee S, Alavian SM, Trautwein C, Tacke F. Comprehensive analysis of mutations in the hepatitis delta virus genome based on full-length sequencing in a nationwide cohort study and evolutionary pattern during disease progression. Clin Microbiol Infect 2015; 21: 510.e11-510.e23 [PMID: 25656625 DOI: 10.1016/j.cmi.2014.12.008]
68. Rizzetto M. Hepatitis D: clinical features and therapy. Dig Dis 2010; 28: 139-143 [PMID: 20460902 DOI: 10.1159/000282077]
69. Kiesslich D, Crispim MA, Santos C, Ferreira Fde L, Fraiji NA, Komninakis SV, Diaz RS. Influence of hepatitis B virus (HBV) genotype on the clinical course of disease in patients coinfected with HBV and hepatitis delta virus. J Infect Dis 2009; 199: 1608-1611 [PMID: 19388852 DOI: 10.1086/598955]
70. Fattovich G, Giustina G, Christensen E, Pantalena M, Zagni I, Realdi G, Schalm SW. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut 2000; 46: 420-426 [PMID: 10673308]
71. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-S50 [PMID: 15508101 DOI: S0016508504015938]
72. Lacombe K, Boyd A, Desvarieux M, Serfaty L, Bonnord P, Gozlan J, Molina JM, Miailhes P, Lascoux-Combe C, Gault E, Girard PM. Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virus. AIDS 2007; 21: 2546-2549 [PMID: 18025897 DOI: 10.1097/QAD.0b013e3282f2a94f]
73. Liao B, Zhang F, Lin S, He H, Liu Y, Zhang J, Xu Y, Yi J, Chen Y, Liu H, Wang Z, Cai W. Epidemiological, clinical and histological characteristics of HBV/HDV co-infection: a retrospective cross-sectional study in Guangdong, China. PLoS One 2014; 9: e115888 [PMID: 25532128 DOI: 10.1371/journal.pone.0115888]
74. Gu XH, Chen Z, Dai RY, Zhang ML, Tang HM, Chen LB, Dong B. Analysis on the clinical features of 507 HDV-infected patients. Cell Biochem Biophys 2014; 70: 1829-1832 [PMID: 25085619 DOI: 10.1007/s12013-014-0137-8]
75. Romeo R, Foglieni B, Casazza G, Spreafico M, Colombo M, Prati D. High serum levels of HDV RNA are predictors of cirrhosis and liver cancer in patients with chronic hepatitis delta. PLoS One 2014; 9: e92062 [PMID: 24658127 DOI: 10.1371/journal. pone.0092062]
76. Rifai K, Wedemeyer H, Rosenau J, Klempnauer J, Strassburg CP, Manns MP, Tillmann HL. Longer survival of liver transplant recipients with hepatitis virus coinfections. Clin Transplant 2007; 21: 258-264 [PMID: 17425755 DOI: 10.1111/j.1399-0012.2006.00636.x]
77. Thomas E, Yoneda M, Schiff ER. Viral hepatitis: past and future of HBV and HDV. Cold Spring Harb Perspect Med 2015; 5: a021345 [PMID: 25646383 DOI: 10.1101/cshperspect.a021345]
78. Aldabe R, Suárez-Amarán L, Usai C, González-Aseguinolaza G. Animal models of chronic hepatitis delta virus infection host-virus immunologic interactions. Pathogens 2015; 4: 46-65 [PMID: 25686091 DOI: 10.3390/pathogens4010046]
79. Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. Lancet 2011; 378: 73-85 [PMID: 21511329 DOI: 10.1016/S0140-6736(10)61931-9]
80. Pascarella S, Negro F. Hepatitis D virus: an update. Liver Int 2011; 31: 7-21 [PMID: 20880077 DOI: 10.1111/j.1478-3231.2010.02320.x]
81. Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013; 57: 1333-1342 [PMID: 23172780 DOI: 10.1002/hep.26141]
82. Messina JP, Humphreys I, Flaxman A, Brown A, Cooke GS, Pybus OG, Barnes E. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology 2015; 61: 77-87 [PMID: 25069599 DOI: 10.1002/hep.27259]
83. Negro F. HCV infection and metabolic syndrome: which is the chicken and which is the egg? Gastroenterology 2012; 142: 1288-1292 [PMID: 22537435 DOI: 10.1053/j.gastro.2011.12.063]
84. Westbrook RH, Dusheiko G. Natural history of hepatitis C. J Hepatol 2014; 61: S58-S68 [PMID: 25443346 DOI: 10.1016/j.jhep.2014.07.012]
85. Pawlotsky JM. New hepatitis C therapies: the toolbox, strategies, and challenges. Gastroenterology 2014; 146: 1176-1192 [PMID: 24631495 DOI: 10.1053/j.gastro.2014.03.003]
86. Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm. J Viral Hepat 2014; 21 Suppl 1: 34-59 [PMID: 24713005 DOI: 10.1111/jvh.12248]
87. Bartenschlager R, Cosset FL, Lohmann V. Hepatitis C virus replication cycle. J Hepatol 2010; 53: 583-585 [PMID: 20579761 DOI: 10.1016/j.jhep.2010.04.015]
88. Joyce MA, Tyrrell DL. The cell biology of hepatitis C virus. Microbes Infect 2010; 12: 263-271 [PMID: 20080204 DOI: 10.1016/j.micinf.2009.12.012]
89. Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327 [PMID: 24115039 DOI: 10.1002/hep.26744]
90. Chayama K, Hayes CN. Hepatitis C virus: How genetic variability affects pathobiology of disease. J Gastroenterol Hepatol 2011; 26 Suppl 1: 83-95 [PMID: 21199518 DOI: 10.1111/j.1440-1746.2010.06550.x]
91. Manns MP, Wedemeyer H, Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-1359 [PMID: 16905701 DOI: 10.1136/gut.2005.076646]
92. Scheel TK, Rice CM. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies. Nat Med 2013; 19: 837-849 [PMID: 23836234 DOI: 10.1038/nm.3248]
93. Roingeard P. Hepatitis C virus diversity and hepatic steatosis. J Viral Hepat 2013; 20: 77-84 [PMID: 23301542 DOI: 10.1111/jvh.12035]
94. Goossens N, Negro F. Is genotype 3 of the hepatitis C virus the new villain? Hepatology 2014; 59: 2403-2412 [PMID: 24155107 DOI: 10.1002/hep.26905]
95. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, Adinolfi LE, Asselah T, Jonsson JR, Smedile A, Terrault N, Pazienza V, Giordani MT, Giostra E, Sonzogni A, Ruggiero G, Marcellin P, Powell EE, George J, Negro F. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642 [PMID: 16697727 DOI: 10.1053/j.gastro.2006.03.014]
96. Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology 2003; 125: 1695-1704 [PMID: 14724822]
97. Fartoux L, Poujol-Robert A, Guéchot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut 2005; 54: 1003-1008 [PMID: 15951550 DOI: 10.1136/gut.2004.050302]
98. Rumi MG, De Filippi F, La Vecchia C, Donato MF, Gallus S, Del Ninno E, Colombo M. Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients. Gut 2005; 54: 402-406 [PMID: 15710990 DOI: 10.1136/gut.2004.048009]
99. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology 1997; 25: 754-758 [PMID: 9049231 DOI: 10.1002/hep.510250344]
100. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350-1356 [PMID: 17680653 DOI: 10.1002/hep.21826]
101. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009; 50: 1142-1154 [PMID: 19395111 DOI: 10.1016/j.jhep.2009.01.019]
102. Probst A, Dang T, Bochud M, Egger M, Negro F, Bochud PY. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat 2011; 18: 745-759 [PMID: 21992794 DOI: 10.1111/j.1365-2893.2011.01481.x]
103. Nkontchou G, Ziol M, Aout M, Lhabadie M, Baazia Y, Mahmoudi A, Roulot D, Ganne-Carrie N, Grando-Lemaire V, Trinchet JC, Gordien E, Vicaut E, Baghad I, Beaugrand M. HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis. J Viral Hepat 2011; 18: e516-e522 [PMID: 21914071 DOI: 10.1111/j.1365-2893.2011.01441.x]
104. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593 [PMID: 23268517 DOI: 10.1001/jama.2012.144878]
105. Kanwal F, Kramer JR, Ilyas J, Duan Z, El-Serag HB. HCV genotype 3 is associated with an increased risk of cirrhosis and hepatocellular cancer in a national sample of U.S. Veterans with HCV. Hepatology 2014; 60: 98-105 [PMID: 24615981 DOI: 10.1002/hep.27095]
106. Heindryckx F, Colle I, Van Vlierberghe H. Experimental mouse models for hepatocellular carcinoma research. Int J Exp Pathol 2009; 90: 367-386 [PMID: 19659896 DOI: 10.1111/j.1365-2613.2009.00656.x]
107. Higgs MR, Chouteau P, Lerat H. ‘Liver let die’: oxidative DNA damage and hepatotropic viruses. J Gen Virol 2014; 95: 991-1004 [PMID: 24496828 DOI: 10.1099/vir.0.059485-0]
108. Nault JC. Pathogenesis of hepatocellular carcinoma according to aetiology. Best Pract Res Clin Gastroenterol 2014; 28: 937-947 [PMID: 25260319 DOI: 10.1016/j.bpg.2014.08.006]
109. Bonilla Guerrero R, Roberts LR. The role of hepatitis B virus integrations in the pathogenesis of human hepatocellular carcinoma. J Hepatol 2005; 42: 760-777 [PMID: 15826727 DOI: 10.1016/j.jhep.2005.02.005]
110. Ringelhan M, O’Connor T, Protzer U, Heikenwalder M. The direct and indirect roles of HBV in liver cancer: prospective markers for HCC screening and potential therapeutic targets. J Pathol 2015; 235: 355-367 [PMID: 25196558 DOI: 10.1002/path.4434]
111. Albeldawi M, Soliman M, Lopez R, Zein NN. Hepatitis C virus-associated primary hepatocellular carcinoma in non-cirrhotic patients. Dig Dis Sci 2012; 57: 3265-3270 [PMID: 22695885 DOI: 10.1007/s10620-012-2260-y]
112. Kawada N, Imanaka K, Kawaguchi T, Tamai C, Ishihara R, Matsunaga T, Gotoh K, Yamada T, Tomita Y. Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis. J Gastroenterol 2009; 44: 1190-1194 [PMID: 19672551 DOI: 10.1007/s00535-009-0112-0]
113. Tsai WL, Chung RT. Viral hepatocarcinogenesis. Oncogene 2010; 29: 2309-2324 [PMID: 20228847 DOI: 10.1038/onc.2010.36]
114. Bréchot C, Gozuacik D, Murakami Y, Paterlini-Bréchot P. Molecular bases for the development of hepatitis B virus (HBV)related hepatocellular carcinoma (HCC). Semin Cancer Biol 2000; 10: 211-231 [PMID: 10936070 DOI: 10.1006/scbi.2000.0321]
115. Jiang S, Yang Z, Li W, Li X, Wang Y, Zhang J, Xu C, Chen PJ, Hou J, McCrae MA, Chen X, Zhuang H, Lu F. Re-evaluation of the carcinogenic significance of hepatitis B virus integration in hepatocarcinogenesis. PLoS One 2012; 7: e40363 [PMID: 22962577 DOI: 10.1371/journal.pone.0040363]
116. Bouchard MJ, Schneider RJ. The enigmatic X gene of hepatitis B virus. J Virol 2004; 78: 12725-12734 [PMID: 15542625 DOI: 10.1128/JVI.78.23.12725-12734.2004]
117. Su Q, Schröder CH, Hofmann WJ, Otto G, Pichlmayr R, Bannasch P. Expression of hepatitis B virus X protein in HBV-infected human livers and hepatocellular carcinomas. Hepatology 1998; 27: 1109-1120 [PMID: 9537452 DOI: 10.1002/hep.510270428]
118. Knoll S, Fürst K, Thomas S, Villanueva Baselga S, Stoll A, Schaefer S, Pützer BM. Dissection of cell context-dependent interactions between HBx and p53 family members in regulation of apoptosis: a role for HBV-induced HCC. Cell Cycle 2011; 10: 3554-3565 [PMID: 22030623 DOI: 10.4161/cc.10.20.17856]
119. Amaddeo G, Cao Q, Ladeiro Y, Imbeaud S, Nault JC, Jaoui D, Gaston Mathe Y, Laurent C, Laurent A, Bioulac-Sage P, Calderaro J, Zucman-Rossi J. Integration of tumour and viral genomic characterizations in HBV-related hepatocellular carcinomas. Gut 2015; 64: 820-829 [PMID: 25021421 DOI: 10.1136/gutjnl-2013-306228]
120. Pang R, Lee TK, Poon RT, Fan ST, Wong KB, Kwong YL, Tse E. Pin1 interacts with a specific serine-proline motif of hepatitis B virus X-protein to enhance hepatocarcinogenesis. Gastroenterology 2007; 132: 1088-1103 [PMID: 17383430 DOI: 10.1053/j.gastro.2006.12.030]
121. Datta S, Banerjee A, Chandra PK, Chakravarty R. Pin1-HBx interaction: a step toward understanding the significance of hepatitis B virus genotypes in hepatocarcinogenesis. Gastroenterology 2007; 133: 727-728; author reply 728-729 [PMID: 17681194 DOI: 10.1053/j.gastro.2007.06.033]
122. Peng Z, Zhang Y, Gu W, Wang Z, Li D, Zhang F, Qiu G, Xie K. Integration of the hepatitis B virus X fragment in hepatocellular carcinoma and its effects on the expression of multiple molecules: a key to the cell cycle and apoptosis. Int J Oncol 2005; 26: 467-473 [PMID: 15645132]
123. Fujimoto A, Totoki Y, Abe T, Boroevich KA, Hosoda F, Nguyen HH, Aoki M, Hosono N, Kubo M, Miya F, Arai Y, Takahashi H, Shirakihara T, Nagasaki M, Shibuya T, Nakano K, Watanabe-Makino K, Tanaka H, Nakamura H, Kusuda J, Ojima H, Shimada K, Okusaka T, Ueno M, Shigekawa Y, Kawakami Y, Arihiro K, Ohdan H, Gotoh K, Ishikawa O, Ariizumi S, Yamamoto M, Yamada T, Chayama K, Kosuge T, Yamaue H, Kamatani N, Miyano S, Nakagama H, Nakamura Y, Tsunoda T, Shibata T, Nakagawa H. Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators. Nat Genet 2012; 44: 760-764 [PMID: 22634756 DOI: 10.1038/ng.2291]
124. Jiang Z, Jhunjhunwala S, Liu J, Haverty PM, Kennemer MI, Guan Y, Lee W, Carnevali P, Stinson J, Johnson S, Diao J, Yeung S, Jubb A, Ye W, Wu TD, Kapadia SB, de Sauvage FJ, Gentleman RC, Stern HM, Seshagiri S, Pant KP, Modrusan Z, Ballinger DG, Zhang Z. The effects of hepatitis B virus integration into the genomes of hepatocellular carcinoma patients. Genome Res 2012; 22: 593-601 [PMID: 22267523 DOI: 10.1101/gr.133926.111]
125. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, Poon RT, Fan ST, Chan KL, Gong Z, Hu Y, Lin Z, Wang G, Zhang Q, Barber TD, Chou WC, Aggarwal A, Hao K, Zhou W, Zhang C, Hardwick J, Buser C, Xu J, Kan Z, Dai H, Mao M, Reinhard C, Wang J, Luk JM. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet 2012; 44: 765-769 [PMID: 22634754 DOI: 10.1038/ng.2295]
126. Park IY, Sohn BH, Yu E, Suh DJ, Chung YH, Lee JH, Surzycki SJ, Lee YI. Aberrant epigenetic modifications in hepatocarcinogenesis induced by hepatitis B virus X protein. Gastroenterology 2007; 132: 1476-1494 [PMID: 17408664 DOI: 10.1053/j.gastro.2007.01.034]
127. Zheng DL, Zhang L, Cheng N, Xu X, Deng Q, Teng XM, Wang KS, Zhang X, Huang J, Han ZG. Epigenetic modification induced by hepatitis B virus X protein via interaction with de novo DNA methyltransferase DNMT3A. J Hepatol 2009; 50: 377-387 [PMID: 19070387 DOI: 10.1016/j.jhep.2008.10.019]
128. Shon JK, Shon BH, Park IY, Lee SU, Fa L, Chang KY, Shin JH, Lee YI. Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription. Virus Res 2009; 139: 14-21 [PMID: 18948152 DOI: 10.1016/j.virusres.2008.09.006]
129. Pollicino T, Vegetti A, Saitta C, Ferrara F, Corradini E, Raffa G, Pietrangelo A, Raimondo G. Hepatitis B virus DNA integration in tumour tissue of a non-cirrhotic HFE-haemochromatosis patient with hepatocellular carcinoma. J Hepatol 2013; 58: 190-193 [PMID: 22989571 DOI: 10.1016/j.jhep.2012.09.005]
130. Ng SA, Lee C. Hepatitis B virus X gene and hepatocarcinogenesis. J Gastroenterol 2011; 46: 974-990 [PMID: 21647825 DOI: 10.1007/s00535-011-0415-9]
131. Motavaf M, Safari S, Saffari Jourshari M, Alavian SM. Hepatitis B virus-induced hepatocellular carcinoma: the role of the virus x protein. Acta Virol 2013; 57: 389-396 [PMID: 24294951]
132. Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51-68 [PMID: 10704474]
133. Liang T, Chen EQ, Tang H. Hepatitis B virus gene mutations and hepatocarcinogenesis. Asian Pac J Cancer Prev 2013; 14: 4509-4513 [PMID: 24083693]
134. Nurainy N, Muljono DH, Sudoyo H, Marzuki S. Genetic study of hepatitis B virus in Indonesia reveals a new subgenotype of genotype B in east Nusa Tenggara. Arch Virol 2008; 153: 1057-1065 [PMID: 18463783 DOI: 10.1007/s00705-008-0092-z]
135. Wang LH, Huang W, Lai MD, Su IJ. Aberrant cyclin A expression and centrosome overduplication induced by hepatitis B virus pre-S2 mutants and its implication in hepatocarcinogenesis. Carcinogenesis 2012; 33: 466-472 [PMID: 22159224 DOI: 10.1093/carcin/bgr296]
136. Chisari FV, Klopchin K, Moriyama T, Pasquinelli C, Dunsford HA, Sell S, Pinkert CA, Brinster RL, Palmiter RD. Molecular pathogenesis of hepatocellular carcinoma in hepatitis B virus transgenic mice. Cell 1989; 59: 1145-1156 [PMID: 2598264]
137. Barone M, Spano D, D’Apolito M, Centra M, Lasalandra C, Capasso M, Di Leo A, Volinia S, Arcelli D, Rosso N, Francavilla A, Tiribelli C, Iolascon A. Gene expression analysis in HBV transgenic mouse liver: a model to study early events related to hepatocarcinogenesis. Mol Med 2006; 12: 115-123 [PMID: 16953557 DOI: 10.2119/2006-00015.Barone]
138. Saitta C, Tripodi G, Barbera A, Bertuccio A, Smedile A, Ciancio A, Raffa G, Sangiovanni A, Navarra G, Raimondo G, Pollicino T. Hepatitis B virus (HBV) DNA integration in patients with occult HBV infection and hepatocellular carcinoma. Liver Int 2015; 35: 2311-2317 [PMID: 25677098 DOI: 10.1111/liv.12807]
139. Toyoda H, Kumada T, Kaneoka Y, Murakami Y. Impact of hepatitis B virus (HBV) X gene integration in liver tissue on hepatocellular carcinoma development in serologically HBV-negative chronic hepatitis C patients. J Hepatol 2008; 48: 43-50 [PMID: 18023912 DOI: 10.1016/j.jhep.2007.08.016]
140. Shi Y, Lan Y, Cao F, Teng Y, Li L, Wang F, Li J, Zhou J, Li Y. Infected hematopoietic stem cells and with integrated HBV DNA generate defective T cells in chronic HBV infection patients. J Viral Hepat 2014; 21: e39-e47 [PMID: 24620791 DOI: 10.1111/jvh.12236]
141. Castello G, Scala S, Palmieri G, Curley SA, Izzo F. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol 2010; 134: 237-250 [PMID: 19910258 DOI: 10.1016/j.clim.2009.10.007]
142. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma. Nat Rev Cancer 2013; 13: 123-135 [PMID: 23344543 DOI: 10.1038/nrc3449]
143. Marra M, Sordelli IM, Lombardi A, Lamberti M, Tarantino L, Giudice A, Stiuso P, Abbruzzese A, Sperlongano R, Accardo M, Agresti M, Caraglia M, Sperlongano P. Molecular targets and oxidative stress biomarkers in hepatocellular carcinoma: an overview. J Transl Med 2011; 9: 171 [PMID: 21985599 DOI: 10.1186/1479-5876-9-171]
144. Koike K, Miyoshi H. Oxidative stress and hepatitis C viral infection. Hepatol Res 2006; 34: 65-73 [PMID: 16364681 DOI: 10.1016/j.hepres.2005.11.001]
145. Farinati F, Cardin R, Degan P, De Maria N, Floyd RA, Van Thiel DH, Naccarato R. Oxidative DNA damage in circulating leukocytes occurs as an early event in chronic HCV infection. Free Radic Biol Med 1999; 27: 1284-1291 [PMID: 10641722]
146. Sumida Y, Nakashima T, Yoh T, Nakajima Y, Ishikawa H, Mitsuyoshi H, Sakamoto Y, Okanoue T, Kashima K, Nakamura H, Yodoi J. Serum thioredoxin levels as an indicator of oxidative stress in patients with hepatitis C virus infection. J Hepatol 2000; 33: 616-622 [PMID: 11059866]
147. Mahmood S, Kawanaka M, Kamei A, Izumi A, Nakata K, Niiyama G, Ikeda H, Hanano S, Suehiro M, Togawa K, Yamada G. Immunohistochemical evaluation of oxidative stress markers in chronic hepatitis C. Antioxid Redox Signal 2004; 6: 19-24 [PMID: 14713333 DOI: 10.1089/152308604771978318]
148. Fujita N, Sugimoto R, Ma N, Tanaka H, Iwasa M, Kobayashi Y, Kawanishi S, Watanabe S, Kaito M, Takei Y. Comparison of hepatic oxidative DNA damage in patients with chronic hepatitis B and C. J Viral Hepat 2008; 15: 498-507 [PMID: 18331251 DOI: 10.1111/j.1365-2893.2008.00972.x]
149. Gabbay E, Zigmond E, Pappo O, Hemed N, Rowe M, Zabrecky G, Cohen R, Ilan Y. Antioxidant therapy for chronic hepatitis C after failure of interferon: results of phase II randomized, double-blind placebo controlled clinical trial. World J Gastroenterol 2007; 13: 5317-5323 [PMID: 17879400 DOI: 10.3748/wjg.v13.i40.5317]
150. Gane EJ, Weilert F, Orr DW, Keogh GF, Gibson M, Lockhart MM, Frampton CM, Taylor KM, Smith RA, Murphy MP. The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 2010; 30: 1019-1026 [PMID: 20492507 DOI: 10.1111/j.1478-3231.2010.02250.x]
151. Ivanov AV, Bartosch B, Smirnova OA, Isaguliants MG, Kochetkov SN. HCV and oxidative stress in the liver. Viruses 2013; 5: 439-469 [PMID: 23358390 DOI: 10.3390/v5020439]
152. Moriya K, Nakagawa K, Santa T, Shintani Y, Fujie H, Miyoshi H, Tsutsumi T, Miyazawa T, Ishibashi K, Horie T, Imai K, Todoroki T, Kimura S, Koike K. Oxidative stress in the absence of inflammation in a mouse model for hepatitis C virus-associated hepatocarcinogenesis. Cancer Res 2001; 61: 4365-4370 [PMID: 11389061]
153. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002; 122: 366-375 [PMID: 11832451]
154. Korenaga M, Wang T, Li Y, Showalter LA, Chan T, Sun J, Weinman SA. Hepatitis C virus core protein inhibits mitochondrial electron transport and increases reactive oxygen species (ROS) production. J Biol Chem 2005; 280: 37481-37488 [PMID: 16150732 DOI: 10.1074/jbc.M506412200]
155. Gong G, Waris G, Tanveer R, Siddiqui A. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-kappa B. Proc Natl Acad Sci USA 2001; 98: 9599-9604 [PMID: 11481452 DOI: 10.1073/pnas.171311298]
156. Qadri I, Iwahashi M, Capasso JM, Hopken MW, Flores S, Schaack J, Simon FR. Induced oxidative stress and activated expression of manganese superoxide dismutase during hepatitis C virus replication: role of JNK, p38 MAPK and AP-1. Biochem J 2004; 378: 919-928 [PMID: 14670077 DOI: 10.1042/BJ20031587]
157. Waris G, Turkson J, Hassanein T, Siddiqui A. Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J Virol 2005; 79: 1569-1580 [PMID: 15650183 DOI: 10.1128/JVI.79.3.1569-1580.2005]
158. Lin W, Tsai WL, Shao RX, Wu G, Peng LF, Barlow LL, Chung WJ, Zhang L, Zhao H, Jang JY, Chung RT. Hepatitis C virus regulates transforming growth factor beta1 production through the generation of reactive oxygen species in a nuclear factor kappaBdependent manner. Gastroenterology 2010; 138: 2509-218, 2518. e1 [PMID: 20230822 DOI: 10.1053/j.gastro.2010.03.008]
159. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology 2008; 134: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]
160. Taniguchi H, Kato N, Otsuka M, Goto T, Yoshida H, Shiratori Y, Omata M. Hepatitis C virus core protein upregulates transforming growth factor-beta 1 transcription. J Med Virol 2004; 72: 52-59 [PMID: 14635011 DOI: 10.1002/jmv.10545]
161. Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med (Maywood) 2008; 233: 109-122 [PMID: 18222966 DOI: 10.3181/0707-MR-190]
162. Nomura-Takigawa Y, Nagano-Fujii M, Deng L, Kitazawa S, Ishido S, Sada K, Hotta H. Non-structural protein 4A of Hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. J Gen Virol 2006; 87: 1935-1945 [PMID: 16760395 DOI: 10.1099/vir.0.81701-0]
163. Kang SM, Kim SJ, Kim JH, Lee W, Kim GW, Lee KH, Choi KY, Oh JW. Interaction of hepatitis C virus core protein with Hsp60 triggers the production of reactive oxygen species and enhances TNF-alpha-mediated apoptosis. Cancer Lett 2009; 279: 230-237 [PMID: 19264393 DOI: 10.1016/j.canlet.2009.02.003]
164. Kawanishi S, Oikawa S. Mechanism of telomere shortening by oxidative stress. Ann N Y Acad Sci 2004; 1019: 278-284 [PMID: 15247029 DOI: 10.1196/annals.1297.047]
165. Sekoguchi S, Nakajima T, Moriguchi M, Jo M, Nishikawa T, Katagishi T, Kimura H, Minami M, Itoh Y, Kagawa K, Tani Y, Okanoue T. Role of cell-cycle turnover and oxidative stress in telomere shortening and cellular senescence in patients with chronic hepatitis C. J Gastroenterol Hepatol 2007; 22: 182-190 [PMID: 17295869 DOI: 10.1111/j.1440-1746.2006.04454.x]
166. Machida K, Cheng KT, Sung VM, Shimodaira S, Lindsay KL, Levine AM, Lai MY, Lai MM. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and protooncogenes. Proc Natl Acad Sci USA 2004; 101: 4262-4267 [PMID: 14999097 DOI: 10.1073/pnas.0303971101]
167. Yen HH, Shih KL, Lin TT, Su WW, Soon MS, Liu CS. Decreased mitochondrial deoxyribonucleic acid and increased oxidative damage in chronic hepatitis C. World J Gastroenterol 2012; 18: 5084-5089 [PMID: 23049218 DOI: 10.3748/wjg.v18.i36.5084]
168. Tardif KD, Mori K, Siddiqui A. Hepatitis C virus subgenomic replicons induce endoplasmic reticulum stress activating an intracellular signaling pathway. J Virol 2002; 76: 7453-7459 [PMID: 12097557]
169. Waris G, Tardif KD, Siddiqui A. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-kappaB and STAT-3. Biochem Pharmacol 2002; 64: 1425-1430 [PMID: 12417255]
170. Ji C. Dissection of endoplasmic reticulum stress signaling in alcoholic and non-alcoholic liver injury. J Gastroenterol Hepatol 2008; 23 Suppl 1: S16-S24 [PMID: 18336657 DOI: 10.1111/j.1440-1746.2007.05276.x]
171. Sano R, Reed JC. ER stress-induced cell death mechanisms. Biochim Biophys Acta 2013; 1833: 3460-3470 [PMID: 23850759 DOI: 10.1016/j.bbamcr.2013.06.028]
172. Yoshida H, Haze K, Yanagi H, Yura T, Mori K. Identification of the cis-acting endoplasmic reticulum stress response element responsible for transcriptional induction of mammalian glucose-regulated proteins. Involvement of basic leucine zipper transcription factors. J Biol Chem 1998; 273: 33741-33749 [PMID: 9837962]
173. Ciccaglione AR, Marcantonio C, Tritarelli E, Equestre M, Vendittelli F, Costantino A, Geraci A, Rapicetta M. Activation of the ER stress gene gadd153 by hepatitis C virus sensitizes cells to oxidant injury. Virus Res 2007; 126: 128-138 [PMID: 17368854 DOI: 10.1016/j.virusres.2007.02.006]
174. Benali-Furet NL, Chami M, Houel L, De Giorgi F, Vernejoul F, Lagorce D, Buscail L, Bartenschlager R, Ichas F, Rizzuto R, Paterlini-Bréchot P. Hepatitis C virus core triggers apoptosis in liver cells by inducing ER stress and ER calcium depletion. Oncogene 2005; 24: 4921-4933 [PMID: 15897896 DOI: 10.1038/sj.onc.1208673]
175. Joyce MA, Walters KA, Lamb SE, Yeh MM, Zhu LF, Kneteman N, Doyle JS, Katze MG, Tyrrell DL. HCV induces oxidative and ER stress, and sensitizes infected cells to apoptosis in SCID/Alb-uPA mice. PLoS Pathog 2009; 5: e1000291 [PMID: 19242562 DOI: 10.1371/journal.ppat.1000291]
176. von dem Bussche A, Machida R, Li K, Loevinsohn G, Khander A, Wang J, Wakita T, Wands JR, Li J. Hepatitis C virus NS2 protein triggers endoplasmic reticulum stress and suppresses its own viral replication. J Hepatol 2010; 53: 797-804 [PMID: 20801537 DOI: 10.1016/j.jhep.2010.05.022]
177. Merquiol E, Uzi D, Mueller T, Goldenberg D, Nahmias Y, Xavier RJ, Tirosh B, Shibolet O. HCV causes chronic endoplasmic reticulum stress leading to adaptation and interference with the unfolded protein response. PLoS One 2011; 6: e24660 [PMID: 21949742 DOI: 10.1371/journal.pone.0024660]
178. Dionisio N, Garcia-Mediavilla MV, Sanchez-Campos S, Majano PL, Benedicto I, Rosado JA, Salido GM, Gonzalez-Gallego J. Hepatitis C virus NS5A and core proteins induce oxidative stress-mediated calcium signalling alterations in hepatocytes. J Hepatol 2009; 50: 872-882 [PMID: 19303156 DOI: 10.1016/j.jhep.2008.12.026]
179. Bartosch B, Thimme R, Blum HE, Zoulim F. Hepatitis C virus-induced hepatocarcinogenesis. J Hepatol 2009; 51: 810-820 [PMID: 19545926 DOI: 10.1016/j.jhep.2009.05.008]
180. Lemon SM, McGivern DR. Is hepatitis C virus carcinogenic? Gastroenterology 2012; 142: 1274-1278 [PMID: 22537433 DOI: 10.1053/j.gastro.2012.01.045]
181. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25: 3834-3847 [PMID: 16799625 DOI: 10.1038/sj.onc.1209562]
182. McGivern DR, Lemon SM. Virus-specific mechanisms of carcinogenesis in hepatitis C virus associated liver cancer. Oncogene 2011; 30: 1969-1983 [PMID: 21258404 DOI: 10.1038/onc.2010.594]
183. Tornesello ML, Buonaguro L, Tatangelo F, Botti G, Izzo F, Buonaguro FM. Mutations in TP53, CTNNB1 and PIK3CA genes in hepatocellular carcinoma associated with hepatitis B and hepatitis C virus infections. Genomics 2013; 102: 74-83 [PMID: 23583669 DOI: 10.1016/j.ygeno.2013.04.001]
184. Liu J, Wang Z, Tang J, Tang R, Shan X, Zhang W, Chen Q, Zhou F, Chen K, Huang A, Tang N. Hepatitis C virus core protein activates Wnt/β-catenin signaling through multiple regulation of upstream molecules in the SMMC-7721 cell line. Arch Virol 2011; 156: 1013-1023 [PMID: 21340743 DOI: 10.1007/s00705-011-0943-x]
185. Higgs MR, Lerat H, Pawlotsky JM. Hepatitis C virus-induced activation of β-catenin promotes c-Myc expression and a cascade of pro-carcinogenetic events. Oncogene 2013; 32: 4683-4693 [PMID: 23108410 DOI: 10.1038/onc.2012.484]
186. Park CY, Choi SH, Kang SM, Kang JI, Ahn BY, Kim H, Jung G, Choi KY, Hwang SB. Nonstructural 5A protein activates beta-catenin signaling cascades: implication of hepatitis C virus-induced liver pathogenesis. J Hepatol 2009; 51: 853-864 [PMID: 19726098 DOI: 10.1016/j.jhep.2009.06.026]
187. Street A, Macdonald A, McCormick C, Harris M. Hepatitis C virus NS5A-mediated activation of phosphoinositide 3-kinase results in stabilization of cellular beta-catenin and stimulation of beta-catenin-responsive transcription. J Virol 2005; 79: 5006-5016 [PMID: 15795286 DOI: 10.1128/JVI.79.8.5006-5016.2005]
188. Munakata T, Nakamura M, Liang Y, Li K, Lemon SM. Down-regulation of the retinoblastoma tumor suppressor by the hepatitis C virus NS5B RNA-dependent RNA polymerase. Proc Natl Acad Sci USA 2005; 102: 18159-18164 [PMID: 16332962 DOI: 10.1073/pnas.0505605102]
189. Hernando E, Nahlé Z, Juan G, Diaz-Rodriguez E, Alaminos M, Hemann M, Michel L, Mittal V, Gerald W, Benezra R, Lowe SW, Cordon-Cardo C. Rb inactivation promotes genomic instability by uncoupling cell cycle progression from mitotic control. Nature 2004; 430: 797-802 [PMID: 15306814 DOI: 10.1038/nature02820]
190. Hassan M, Ghozlan H, Abdel-Kader O. Activation of RB/E2F signaling pathway is required for the modulation of hepatitis C virus core protein-induced cell growth in liver and non-liver cells. Cell Signal 2004; 16: 1375-1385 [PMID: 15381253 DOI: 10.1016/j.cellsig.2004.04.005]
191. Lai CK, Jeng KS, Machida K, Cheng YS, Lai MM. Hepatitis C virus NS3/4A protein interacts with ATM, impairs DNA repair and enhances sensitivity to ionizing radiation. Virology 2008; 370: 295-309 [PMID: 17931678 DOI: 10.1016/j.virol.2007.08.037]
192. Machida K, McNamara G, Cheng KT, Huang J, Wang CH, Comai L, Ou JH, Lai MM. Hepatitis C virus inhibits DNA damage repair through reactive oxygen and nitrogen species and by interfering with the ATM-NBS1/Mre11/Rad50 DNA repair pathway in monocytes and hepatocytes. J Immunol 2010; 185: 6985-6998 [PMID: 20974981 DOI: 10.4049/jimmunol.1000618]
193. Pal S, Polyak SJ, Bano N, Qiu WC, Carithers RL, Shuhart M, Gretch DR, Das A. Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol 2010; 25: 627-634 [PMID: 20074151 DOI: 10.1111/j.1440-1746.2009.06128.x]
194. Hoare M, Das T, Alexander G. Ageing, telomeres, senescence, and liver injury. J Hepatol 2010; 53: 950-961 [PMID: 20739078 DOI: 10.1016/j.jhep.2010.06.009]
195. Borel F, Konstantinova P, Jansen PL. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012; 56: 1371-1383 [PMID: 22314424 DOI: 10.1016/j.jhep.2011.11.026]
196. Fornari F, Gramantieri L, Giovannini C, Veronese A, Ferracin M, Sabbioni S, Calin GA, Grazi GL, Croce CM, Tavolari S, Chieco P, Negrini M, Bolondi L. MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 2009; 69: 5761-5767 [PMID: 19584283 DOI: 10.1158/0008-5472.CAN-08-4797]
197. Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer 2014; 3: 71-84 [PMID: 24944998 DOI: 10.1159/000343863]
198. Yamashita T, Kaneko S. Orchestration of hepatocellular carcinoma development by diverse liver cancer stem cells. J Gastroenterol 2014; 49: 1105-1110 [PMID: 24647548 DOI: 10.1007/s00535-014-0951-1]
199. Oliva J, French BA, Qing X, French SW. The identification of stem cells in human liver diseases and hepatocellular carcinoma. Exp Mol Pathol 2010; 88: 331-340 [PMID: 20080086 DOI: 10.1016/j.yexmp.2010.01.003]
200. Lu JW, Chang JG, Yeh KT, Chen RM, Tsai JJ, Hu RM. Overexpression of Thy1/CD90 in human hepatocellular carcinoma is associated with HBV infection and poor prognosis. Acta Histochem 2011; 113: 833-838 [PMID: 21272924 DOI: 10.1016/j.acthis.2011.01.001]
201. Yeh CT, Kuo CJ, Lai MW, Chen TC, Lin CY, Yeh TS, Lee WC. CD133-positive hepatocellular carcinoma in an area endemic for hepatitis B virus infection. BMC Cancer 2009; 9: 324 [PMID: 19744348 DOI: 10.1186/1471-2407-9-324]
202. Arzumanyan A, Friedman T, Ng IO, Clayton MM, Lian Z, Feitelson MA. Does the hepatitis B antigen HBx promote the appearance of liver cancer stem cells? Cancer Res 2011; 71: 3701-3708 [PMID: 21464043 DOI: 10.1158/0008-5472. CAN-10-3951]
203. Wang C, Yang W, Yan HX, Luo T, Zhang J, Tang L, Wu FQ, Zhang HL, Yu LX, Zheng LY, Li YQ, Dong W, He YQ, Liu Q, Zou SS, Lin Y, Hu L, Li Z, Wu MC, Wang HY. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology 2012; 55: 108-120 [PMID: 21932402 DOI: 10.1002/hep.24675]
204. Li CH, Wang YJ, Dong W, Xiang S, Liang HF, Wang HY, Dong HH, Chen L, Chen XP. Hepatic oval cell lines generate hepatocellular carcinoma following transfection with HBx gene and treatment with aflatoxin B1 in vivo. Cancer Lett 2011; 311: 1-10 [PMID: 21821357 DOI: 10.1016/j.canlet.2011.05.035]
205. Kimura O, Kondo Y, Kogure T, Kakazu E, Ninomiya M, Iwata T, Morosawa T, Shimosegawa T. Expression of EpCAM increases in the hepatitis B related and the treatment-resistant hepatocellular carcinoma. Biomed Res Int 2014; 2014: 172913 [PMID: 24696843 DOI: 10.1155/2014/172913]
206. Fan H, Zhang H, Pascuzzi PE, Andrisani O. Hepatitis B virus X protein induces EpCAM expression via active DNA demethylation directed by RelA in complex with EZH2 and TET2. Oncogene 2015; Epub ahead of print [PMID: 25893293 DOI: 10.1038/onc.2015.122]
207. Ali N, Allam H, May R, Sureban SM, Bronze MS, Bader T, Umar S, Anant S, Houchen CW. Hepatitis C virus-induced cancer stem cell-like signatures in cell culture and murine tumor xenografts. J Virol 2011; 85: 12292-12303 [PMID: 21937640 DOI: 10.1128/JVI.05920-11]
208. Machida K, Tsukamoto H, Mkrtchyan H, Duan L, Dynnyk A, Liu HM, Asahina K, Govindarajan S, Ray R, Ou JH, Seki E, Deshaies R, Miyake K, Lai MM. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA 2009; 106: 1548-1553 [PMID: 19171902 DOI: 10.1073/pnas.0807390106]
209. Machida K, Chen CL, Liu JC, Kashiwabara C, Feldman D, French SW, Sher L, Hyeongnam JJ, Tsukamoto H. Cancer stem cells generated by alcohol, diabetes, and hepatitis C virus. J Gastroenterol Hepatol 2012; 27 Suppl 2: 19-22 [PMID: 22320911 DOI: 10.1111/j.1440-1746.2011.07010.x]
210. Papatheodoridis GV, Chan HL, Hansen BE, Janssen HL, Lampertico P. Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-967 [PMID: 25595883 DOI: 10.1016/j.jhep.2015.01.002]